Johnson & Johnson Innovative Medicine

We’re restoring the true meaning of healthcare—developing advanced treatments and smarter and less invasive solutions for today’s most complex diseases. See how we're connecting the best of Health&Care for every patient and provider. https://lnkd.in/eW-mXA49

This American Pharmacists Month, we're proud of our continued partnership with the American Pharmacists Association to celebrate and highlight the incredible work of pharmacists in our communities.    Check out their inspiring #APhM2024 video featuring a local community pharmacy in Maquoketa, Iowa, which highlights how pharmacists are truly #Indispensable to their community.   #APhM2024 #CaringForOurCommunities

Attending Psych Congress 2024?  Come visit us in the Exhibit Hall Theater for an insightful session titled, “Breaking Down the Language Barrier in Patient-Provider Discussions About Anhedonia in MDD” this Thursday.  During the session, Craig Chepke, MD, DFAPA and Rakesh Jain, MD, MPH will share perspectives on how providers can better speak with patients about their depressive symptoms and identify whether they are experiencing symptoms of anhedonia. Also, be sure to take a look at the full agenda and check out the other educational sessions J&J is sponsoring at the Congress: https://lnkd.in/ekhPbzW6 #PsychCongress2024 #Depression #Schizophrenia #MentalHealth #Neuroscience

Are you heading to the 2024 Society for Immunotherapy of Cancer (SITC) annual meeting in Houston, Texas? Join us at JLABS @ TMC on November 8 for an enriching panel discussion with industry experts including Crystal Mackall, Dr. Ignacio Melero Bermejo, Stephen Pitt, Ph.D., Charles Drake, Colin Moran, Bob Radinsky, and Allison Rhines. Secure your spot today to gain valuable insights into the future of immunology and explore potential collaboration opportunities. RSVP at  https://lnkd.in/eF9_ZSzu

Our researchers are investigating inhibition of a potential coagulation or clotting target known as Factor XIa that may help advance care for people at risk of thrombotic events, like stroke, in our comprehensive Phase 3 Librexia clinical trial program with Bristol Myers Squibb. Through our comprehensive clinical trial program, we aim to improve outcomes for patients living with thrombotic conditions. #WorldStrokeDay

#GeneTherapy has the potential to offer promising treatment options for patients with retinal diseases, such as #GeographicAthrophy (GA). That’s why we’re working to bring a new era of treatments with potentially sight-saving #GeneTherapies to preserve and restore sight.     This #BlindnessAwarenessMonth, learn how our team is harnessing the best science to find solutions for those living with blinding #RetinalDisease: bit.ly/EyesOnGenes    #JNJSpecialtyOphthalmology

In honor of #HealthLiteracyMonth, we’re excited to share the most recent episode of our Take 10 podcast series where Donna Hodge sits down with Bill K. — a former engineer and father from Missouri living with multiple myeloma. Since his diagnosis in 2018, Bill has become an inspiring advocate for patients, showing how health literacy can transform the healthcare journey.     Their conversation is a timely exploration of the ways in which patients can partner with their healthcare teams to make informed decisions together.     Listen to the full episode below and don't forget to subscribe on Apple Podcasts and Spotify for more episodes!    https://lnkd.in/eFayxAkZ    #Take10Podcast #PatientEmpowerment #JNJOncology 

For more than two decades, we have been dedicated to developing novel and effective therapies, with a relentless focus on individuals living with chronic conditions such as Crohn’s disease (CD) who experience persistent and debilitating symptoms. We are proud to present Phase 3 data from our studies evaluating the efficacy and safety of a novel treatment option for CD. We look forward to engaging in meaningful conversations about our latest data with experts at #ACG2024. Learn more about these findings: https://lnkd.in/efgeS_QT #JNJImmunology

We’re excited to be at this year’s 18th International Congress on Neuromuscular Diseases (ICNMD 2024) in Australia! Join us at our lunch symposium (29th October), visit us at booth #200, or stop by any of our four accepted posters and oral presentation, as we share our latest data from our research program on generalized myasthenia gravis (gMG). We look forward to connecting with neurology professionals from across the world. Together, we hope to make a difference in the lives of patients who live with neurological autoantibody-driven diseases, such as gMG. Learn more: https://lnkd.in/eVVwAnkH #JNJNeuroscience #JNJImmunology

We’re excited to unveil our latest gastroenterology data at this week’s #ACG2024. Buoyed by researchers with deep knowledge and scientific understanding of the immune system, we’re committed to developing transformative therapies for patients around the globe suffering from inflammatory bowel disease (IBD). We look forward to continuing our development of treatment options to provide choice and flexibility for patients and providers. Learn more about our work here: https://lnkd.in/egZUNWEj #JNJImmunology